ico therapeutics inc (ICOTF) Key Developments
iCo Therapeutics Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015
May 28 15
iCo Therapeutics Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company incurred a total comprehensive loss of $252,397 (loss per share of $0.00), compared to total comprehensive earnings of $1,365,068 (earnings per share of $0.02) for the quarter ended March 31, 2014, representing an increased loss of $1,617,465. The increase is primarily a result of changes related to holdings in Immune Pharmaceuticals Inc.
iCo Therapeutics Inc. Reports Financial Results for the Year Ended December 31, 2014
Apr 27 15
iCo Therapeutics Inc. reported financial results for the year ended December 31, 2014. The company incurred a total comprehensive loss of CAD,079,657 for the year ended December 31, 2014 compared to a total loss of CAD 5,918,965 for the year ended 2013, representing a decrease of CAD 3,839,308. The decrease in its net and comprehensive loss was principally caused by a reduction of clinical trial costs associated with the iDEAL study.
iCo Therapeutics Inc., Annual General Meeting, Jun 26, 2015
Apr 27 15
iCo Therapeutics Inc., Annual General Meeting, Jun 26, 2015. Location: 595 Burrard Street, Suite 2600.
iCo Therapeutics Seeks Acquisitions
Apr 27 15
iCo Therapeutics Inc. (TSXV:ICO) is looking for acquisitions. Andrew Rae, President and Chief Executive Officer of iCo Therapeutics states, "We remain committed to our oral Amphotericin B clinical study plans and continue to assess complimentary assets which the Company may consider in-licensing or acquiring."
iCo Therapeutics Inc., Annual General Meeting, May 22, 2015
Mar 23 15
iCo Therapeutics Inc., Annual General Meeting, May 22, 2015. Location: Blake, Cassels & Graydon LLP.